Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.


Pipeline

 

Place: Japan

Development No. Therapeutic Category Stage
T-4288 Antibacterial agent (Fluoroketolide antibiotic) Phase 3
T-817MA Treatment for Alzheimer's disease Phase 2

(As of Aug. 2017)

Place: Overseas

Development No. Therapeutic Category Stage
T-3811 Antibacterial agent (Quinolone antibiotic) NDA filing (China)
T-705 Antiviral agent (Anti-influenza virus agent) Phase 3 (U.S.)
T-817MA Treatment for Alzheimer's disease Phase 2 (U.S.)
T-2307 Antifungal agent Phase 1 (U.S.)

FUJIFUILM group will conduct development in the foreign country.

(As of Aug. 2017)

Toyama Chemical Co., Ltd. has following patent rights of the compounds of development number described above.
In these countries, acts of making, selling or offering to sell these compounds infringe the following patent rights of Toyama Chemical Co., Ltd. without the permission of Toyama Chemical Co., Ltd.
Please make sure not to infringe patent rights of Toyama Chemical Co., Ltd.
T-705

US patent No. RE43748, EP patent No. 1112743, Chinese patent No. ZL99809897.3, Japanese patent No. 3453362

T-3811

US patents Nos. 6025370 and 6337399, EP patents Nos. 0882725 and 1031569, Chinese patents Nos. ZL01101232.3 and ZL98810627.2, Japanese patents Nos. 3031722 and 3281872

T-817MA

US patent No. RE43676, EP patent No. 1437353, Chinese patent No. ZL02820645.2, Japanese patent No. 4398247

T-2307

US patent No. 7291617, EP patent No. 1481966, Chinese patent No. ZL03807452.4, Japanese patent No. 4320260

Related Information

Main business fields that TOYAMA CHEMICAL concentrates.


Footer starts here.

Pages ends here.
Move to top of the page.